Stock Scan Q4 2017 – Q3 Reporting Chops $70bn From Pharma
Executive Summary
Big pharma stocks lost value overall in the fourth quarter of 2017 despite good performances from Asian companies and Kåre Schultz taking over at Teva.
You may also be interested in...
In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too
Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.
Non-Inhibitor Data Secure Roche's Competitive Position In Hemophilia A
Roche's Genentech reported positive top-line Phase III results for Hemlibra in a second hemophilia A population – patients without inhibitors – just four days after its approval for patients with inhibitors, which will broaden the product's market and may improve its competitive position.